DYAI
Price
$1.23
Change
-$0.01 (-0.81%)
Updated
Apr 17 closing price
Capitalization
37.01M
19 days until earnings call
VYNE
Price
$1.85
Change
+$0.03 (+1.65%)
Updated
Apr 17 closing price
Capitalization
28.14M
Ad is loading...

DYAI vs VYNE

Header iconDYAI vs VYNE Comparison
Open Charts DYAI vs VYNEBanner chart's image
Dyadic International
Price$1.23
Change-$0.01 (-0.81%)
Volume$14.07K
Capitalization37.01M
VYNE Therapeutics
Price$1.85
Change+$0.03 (+1.65%)
Volume$79.3K
Capitalization28.14M
DYAI vs VYNE Comparison Chart
Loading...
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DYAI vs. VYNE commentary
Apr 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DYAI is a Hold and VYNE is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 19, 2025
Stock price -- (DYAI: $1.23 vs. VYNE: $1.85)
Brand notoriety: DYAI and VYNE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DYAI: 33% vs. VYNE: 59%
Market capitalization -- DYAI: $37.01M vs. VYNE: $28.14M
DYAI [@Biotechnology] is valued at $37.01M. VYNE’s [@Biotechnology] market capitalization is $28.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DYAI’s FA Score shows that 0 FA rating(s) are green whileVYNE’s FA Score has 1 green FA rating(s).

  • DYAI’s FA Score: 0 green, 5 red.
  • VYNE’s FA Score: 1 green, 4 red.
According to our system of comparison, VYNE is a better buy in the long-term than DYAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DYAI’s TA Score shows that 4 TA indicator(s) are bullish while VYNE’s TA Score has 5 bullish TA indicator(s).

  • DYAI’s TA Score: 4 bullish, 4 bearish.
  • VYNE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, VYNE is a better buy in the short-term than DYAI.

Price Growth

DYAI (@Biotechnology) experienced а +2.50% price change this week, while VYNE (@Biotechnology) price change was +25.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.03%. For the same industry, the average monthly price growth was -13.25%, and the average quarterly price growth was -24.49%.

Reported Earning Dates

DYAI is expected to report earnings on May 08, 2025.

VYNE is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Biotechnology (+7.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DYAI($37M) has a higher market cap than VYNE($28.1M). DYAI YTD gains are higher at: -29.714 vs. VYNE (-44.776). DYAI has higher annual earnings (EBITDA): -7.42M vs. VYNE (-43.63M). VYNE has more cash in the bank: 61.5M vs. DYAI (9.92M). VYNE has less debt than DYAI: VYNE (99K) vs DYAI (5.37M). DYAI has higher revenues than VYNE: DYAI (3.37M) vs VYNE (501K).
DYAIVYNEDYAI / VYNE
Capitalization37M28.1M132%
EBITDA-7.42M-43.63M17%
Gain YTD-29.714-44.77666%
P/E RatioN/A0.71-
Revenue3.37M501K672%
Total Cash9.92M61.5M16%
Total Debt5.37M99K5,424%
FUNDAMENTALS RATINGS
DYAI vs VYNE: Fundamental Ratings
DYAI
VYNE
OUTLOOK RATING
1..100
9123
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
6262
P/E GROWTH RATING
1..100
611
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VYNE's Valuation (53) in the Pharmaceuticals Major industry is somewhat better than the same rating for DYAI (94) in the Biotechnology industry. This means that VYNE’s stock grew somewhat faster than DYAI’s over the last 12 months.

VYNE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as DYAI (100) in the Biotechnology industry. This means that VYNE’s stock grew similarly to DYAI’s over the last 12 months.

VYNE's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as DYAI (98) in the Biotechnology industry. This means that VYNE’s stock grew similarly to DYAI’s over the last 12 months.

VYNE's Price Growth Rating (62) in the Pharmaceuticals Major industry is in the same range as DYAI (62) in the Biotechnology industry. This means that VYNE’s stock grew similarly to DYAI’s over the last 12 months.

VYNE's P/E Growth Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for DYAI (61) in the Biotechnology industry. This means that VYNE’s stock grew somewhat faster than DYAI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DYAIVYNE
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
76%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 12 days ago
87%
Bearish Trend 12 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
88%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Ad is loading...
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VYNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
SPY526.410.75
+0.14%
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla
BTC.X84450.805000-444.945300
-0.52%
Bitcoin cryptocurrency

DYAI and

Correlation & Price change

A.I.dvisor tells us that DYAI and FBRX have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DYAI and FBRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYAI
1D Price
Change %
DYAI100%
-0.81%
FBRX - DYAI
28%
Poorly correlated
+1.10%
CGTX - DYAI
27%
Poorly correlated
-0.21%
APLS - DYAI
26%
Poorly correlated
+0.22%
VYNE - DYAI
24%
Poorly correlated
+1.65%
NAUT - DYAI
23%
Poorly correlated
+4.80%
More

VYNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, VYNE has been loosely correlated with ELVN. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if VYNE jumps, then ELVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VYNE
1D Price
Change %
VYNE100%
+1.65%
ELVN - VYNE
40%
Loosely correlated
+2.86%
IRON - VYNE
40%
Loosely correlated
+2.84%
KOD - VYNE
35%
Loosely correlated
+20.34%
SPRB - VYNE
34%
Loosely correlated
-3.50%
IDYA - VYNE
33%
Loosely correlated
+5.56%
More